FDMT
4D Molecular Therapeutics, Inc.
There isn't enough reported data to score FDMT yet.
FDMT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
FDMT's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
FDMT PE Valuation
FDMT has no meaningful PE right now: it lost money over the past year.
FDMT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect FDMT's losses to grow, with revenue declining.
FDMT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.70 | +$1.05 |
| Q2 2026 | -$2.63 | +$0.90 |
| Q1 2026 | -$2.57 | +$0.61 |
| Q4 2025 | -$2.42 | +$0.56 |
| Q3 2025 | -$3.75 | -$0.84 |
| Q2 2025 | -$3.53 | -$1.17 |
| Q1 2025 | -$3.18 | -$0.68 |
| Q4 2024 | -$2.98 | -$0.26 |
FDMT is still losing money, but far less than before: $2.70 per share over the past year, against $5.43 at its worst in late 2019.
FDMT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.1M | +4506% |
| Q2 2026 | $3.8M | +25107% |
| Q1 2026 | $3M | +21664% |
| Q4 2025 | $85.1M | +8508900% |
| Q3 2025 | $90K | +2900% |
| Q2 2025 | $15K | +200% |
| Q1 2025 | $14K | -50% |
| Q3 2024 | $3K | -100% |
FDMT's revenue has grown year over year for six quarters in a row: $4M last quarter, up 4506% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1959% | +66024 points |
| Q2 2026 | -2037% | +394336 points |
| Q1 2026 | -2416% | +380591 points |
| Q4 2025 | 17% | +5611717 points |
| Q3 2025 | -67983% | +1636417 points |
| Q2 2025 | -396373% | +452747 points |
| Q1 2025 | -383007% | -246807 points |
| Q4 2024 | -5611700% | N/A |
FDMT's operating margin was −1959% last quarter, up 66024 points from the same quarter a year ago.
FDMT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$56.8M | -$10.4M |
| Q1 2026 | -$68.1M | -$19.7M |
| Q4 2025 | $28.6M | +$75.4M |
| Q3 2025 | -$46.4M | -$15.2M |
| Q2 2025 | -$43.4M | -$12.9M |
| Q1 2025 | -$48.4M | -$18.6M |
| Q4 2024 | -$46.8M | -$21.6M |
| Q3 2024 | -$31.2M | -$29.6M |
FDMT has burned cash in almost every quarter: −$143M over the past year, against −$170M the year before.
FDMT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +2M shares |
| 1 year | +29% | +16.1M shares |
| 3 years | +71% | +30M shares |
| 5 years | +167% | +45.2M shares |
| Available history | +387% | +57.4M shares |
FDMT has 72M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
FDMT Net Leverage
FDMT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
FDMT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 31.2 | Neutral |
FDMT's weekly RSI is 51 (neutral) and its Stochastic is 31 (neutral).
FDMT PE vs Healthcare Sector
FDMT has no meaningful PE right now: it lost money over the past year.
FDMT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.6 | 3.7% below |
| 20 week MA | $12.7 | 4.6% below |
| 50 week MA | $10.6 | 15% above |
| 100 week MA | $8.21 | 48% above |
| 200 week MA | $13.1 | 7.3% below |
FDMT's trend is mixed: it's above two of its five weekly moving averages, and 7.3% below its 200-week average.
FDMT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $40.0 | -1.2% |
| 2021 | $40.0 | $22.7 | -43% |
| 2022 | $22.7 | $21.6 | -5% |
| 2023 | $21.6 | $20.3 | -6.2% |
| 2024 | $20.3 | $5.55 | -73% |
| 2025 | $5.55 | $7.97 | +44% |
| 2026 YTD | $7.97 | $12.1 | +52% |
FDMT is up 52% so far in 2026, after finishing lower in five of the previous six years.